Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in:

Open Access 01-08-2024 | Glioblastoma | Review

The role of IL-17 in the pathogenesis and treatment of glioblastoma—an update on the state of the art and future perspectives

Authors: Dariusz Łaszczych, Aleksandra Czernicka, Karol Gostomczyk, Łukasz Szylberg, Jędrzej Borowczak

Published in: Medical Oncology | Issue 8/2024

Login to get access

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor, which, despite significant progress made in the last years in the field of neuro-oncology, remains an incurable disease. GBM has a poor prognosis with a median survival of 12–15 months, and its aggressive clinical course is related to rapid growth, extensive infiltration of adjacent tissues, resistance to chemotherapy, radiotherapy and immunotherapy, and frequent relapse. Currently, several molecular biomarkers are used in clinical practice to predict patient prognosis and response to treatment. However, due to the overall unsatisfactory efficacy of standard multimodal treatment and the remaining poor prognosis, there is an urgent need for new biomarkers and therapeutic strategies for GBM. Recent evidence suggests that GBM tumorigenesis is associated with crosstalk between cancer, immune and stromal cells mediated by various cytokines. One of the key factors involved in this process appears to be interleukin-17 (IL-17), a pro-inflammatory cytokine that is significantly upregulated in the serum and tissue of GBM patients. IL-17 plays a key role in tumorigenesis, angiogenesis, and recurrence of GBM by activating pro-oncogenic signaling pathways and promoting cell survival, proliferation, and invasion. IL-17 facilitates the immunomodulation of the tumor microenvironment by promoting immune cells infiltration and cytokine secretion. In this article we review the latest scientific reports to provide an update on the role of IL-17 role in tumorigenesis, tumor microenvironment, diagnosis, prognosis, and treatment of GBM.
Literature
1.
2.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef
3.
4.
5.
Rodriguez SMB, Staicu G-A, Sevastre A-S, Baloi C, Ciubotaru V, Dricu A, et al. Glioblastoma stem cells—useful tools in the battle against cancer. Int J Mol Sci. 2022;23:4602.PubMedPubMedCentralCrossRef
6.
7.
8.
9.
Wang B, Zhao C-H, Sun G, Zhang Z-W, Qian B-M, Zhu Y-F, et al. IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K/Akt1/NF-κB-p65. Cancer Lett. 2019;447:93–104.PubMedCrossRef
10.
Borowczak J, Szczerbowski K, Maniewski M, Kowalewski A, Janiczek-Polewska M, Szylberg A, et al. The role of inflammatory cytokines in the pathogenesis of colorectal carcinoma—recent findings and review. Biomedicines. 2022;10:1670.PubMedPubMedCentralCrossRef
11.
12.
13.
14.
15.
16.
17.
Feng Y, Wang J, Tan D, Cheng P, Wu A. Relationship between circulating inflammatory factors and glioma risk and prognosis: a meta-analysis. Cancer Med. 2019;8:7454–68.PubMedPubMedCentralCrossRef
18.
Bender DE, Schaettler MO, Sheehan KC, Johanns TM, Dunn GP. Cytokine profiling in plasma from patients with brain tumors versus healthy individuals using 2 different multiplex immunoassay platforms. Biomark Insights. 2021;16:11772719211006666.PubMedPubMedCentralCrossRef
19.
Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, et al. Immune classifications with cytotoxic CD8+ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. Oncoimmunology. 2017;6:e1321186.PubMedPubMedCentralCrossRef
20.
Cui X, Xu Z, Zhao Z, Sui D, Ren X, Huang Q, et al. Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci. 2013;9:134–41.PubMedPubMedCentralCrossRef
21.
Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17:1433.PubMedPubMedCentralCrossRef
22.
23.
24.
Milovanovic J, Arsenijevic A, Stojanovic B, Kanjevac T, Arsenijevic D, Radosavljevic G, et al. Interleukin-17 in chronic inflammatory neurological diseases. Front Immunol. 2020;11:947.PubMedPubMedCentralCrossRef
25.
26.
Castro G, Liu X, Ngo K, De Leon-Tabaldo A, Zhao S, Luna-Roman R, et al. RORγt and RORα signature genes in human Th17 cells. PLoS ONE. 2017;12:e0181868.PubMedPubMedCentralCrossRef
27.
28.
29.
30.
31.
Li S, Na R, Li X, Zhang Y, Zheng T. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188758.PubMedCrossRef
32.
33.
Hu J, Mao Y, Li M, Lu Y. The profile of Th17 subset in glioma. Int Immunopharmacol. 2011;11:1173–9.PubMedCrossRef
34.
Yu W, Hu J, Le H, Lu Y, Xu W, Yu W, et al. Tumstatin attenuates the promotion effect of IL-17 secreted by Th17 cells on the stemness maintenance of glioma cells. Pathol Res Pract. 2021;223:153463.PubMedCrossRef
35.
Hu J, Ye H, Zhang D, Liu W, Li M, Mao Y, et al. U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol Lett. 2013;6:993–9.PubMedPubMedCentralCrossRef
36.
37.
38.
39.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, et al. Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: revisiting molecular interactions. Biomed Pharmacother. 2023;158:114204.PubMedCrossRef
40.
Parajuli P, Anand R, Mandalaparty C, Suryadevara R, Sriranga PU, Michelhaugh SK, et al. Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal. Oncotarget. 2016;7:6121–35.PubMedPubMedCentralCrossRef
41.
42.
43.
Mitra P, Vaughan PS, Stein JL, Stein GS, van Wijnen AJ. Purification and functional analysis of a novel leucine-zipper/nucleotide-fold protein, BZAP45, stimulating cell cycle regulated histone H4 gene transcription. Biochemistry. 2001;40:10693–9.PubMedCrossRef
44.
Luo A, Qiao N, Hu K, Xu H, Xie M, Jiang Y, et al. BZW1 is a prognostic and immunological biomarker in pancreatic adenocarcinoma. Medicine. 2023;103:e37092.PubMedCentralCrossRef
45.
Zhao L, Song C, Li Y, Yuan F, Zhao Q, Dong H, et al. BZW1 as an oncogene is associated with patient prognosis and the immune microenvironment in glioma. Genomics. 2023;115:110602.PubMedCrossRef
46.
Jung Y, Ahn S-H, Park H, Park SH, Choi K, Choi C, et al. MCP-1 and MIP-3α secreted from necrotic cell-treated glioblastoma cells promote migration/infiltration of microglia. Cell Physiol Biochem. 2018;48:1332–46.PubMedCrossRef
47.
Jin P, Shin S-H, Chun Y-S, Shin H-W, Shin YJ, Lee Y, et al. Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-κB signaling pathway. Oncogene. 2018;37:3070–87.PubMedCrossRef
48.
Tang F, Zhao Y, Zhang Q, Wei W, Tian S, Li C, et al. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment. CNS Neurosci Ther. 2021;27:951–62.PubMedPubMedCentralCrossRef
49.
50.
51.
52.
Wojkowska DW, Szpakowski P, Glabinski A. Interleukin 17A promotes lymphocytes adhesion and induces CCL2 and CXCL1 release from brain endothelial cells. Int J Mol Sci. 2017;18:1000.PubMedPubMedCentralCrossRef
53.
54.
Singh Gautam A, Kumar SR. Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation. Drug Discov Today. 2023;28:103517.PubMedCrossRef
55.
Kawanokuchi J, Shimizu K, Nitta A, Yamada K, Mizuno T, Takeuchi H, et al. Production and functions of IL-17 in microglia. J Neuroimmunol. 2008;194:54–61.PubMedCrossRef
56.
You T, Bi Y, Li J, Zhang M, Chen X, Zhang K, et al. IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling. Sci Rep. 2017;7:41779.PubMedPubMedCentralCrossRef
57.
Henrik Heiland D, Ravi VM, Behringer SP, Frenking JH, Wurm J, Joseph K, et al. Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun. 2019;10:2541.PubMedPubMedCentralCrossRef
58.
Zhang C, Wang Z, Liu H, Wang Z, Jia W. Characterization of tumor-associated reactive astrocytes in gliomas by single-cell and bulk tumor sequencing. Front Neurol. 2023;14:1193844.PubMedPubMedCentralCrossRef
59.
Paladugu M, Thakur A, Lum LG, Mittal S, Parajuli P. Generation and immunologic functions of Th17 cells in malignant gliomas. Cancer Immunol Immunother CII. 2013;62:75–86.PubMedCrossRef
60.
Couto M, Coelho-Santos V, Santos L, Fontes-Ribeiro C, Silva AP, Gomes CMF. The interplay between glioblastoma and microglia cells leads to endothelial cell monolayer dysfunction via the interleukin-6-induced JAK2/STAT3 pathway. J Cell Physiol. 2019;234:19750–60.PubMedCrossRef
61.
Hori T, Sasayama T, Tanaka K, Koma Y-I, Nishihara M, Tanaka H, et al. Tumor-associated macrophage related interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastoma. J Clin Neurosci. 2019;68:281–9.PubMedCrossRef
62.
Wang Q, He Z, Huang M, Liu T, Wang Y, Xu H, et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nat Commun. 2018;9:559.PubMedPubMedCentralCrossRef
63.
Li W, Cai H, Ren L, Yang Y, Yang H, Liu J, et al. Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB /IL-6/STAT3 and JNK/PTX3 pathways. Acta Pharm Sin B. 2022;12:4390–406.PubMedPubMedCentralCrossRef
64.
Gu J, Wang J, Liu X, Sai K, Mai J, Xing F, et al. IL-6 derived from therapy-induced senescence facilitates the glycolytic phenotype in glioblastoma cells. Am J Cancer Res. 2021;11:458–78.PubMedPubMedCentral
65.
66.
Kim R-K, Suh Y, Hwang E, Yoo K-C, Choi K-S, An S, et al. PKCδ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback. Oncogene. 2015;34:5749–59.PubMedCrossRef
67.
68.
Montaner J, Ramiro L, Simats A, Hernández-Guillamon M, Delgado P, Bustamante A, et al. Matrix metalloproteinases and ADAMs in stroke. Cell Mol Life Sci CMLS. 2019;76:3117–40.PubMedCrossRef
69.
Song Y, Yang JM. Role of interleukin (IL)-17 and T-helper (Th)17 cells in cancer. Biochem Biophys Res Commun. 2017;493:1–8.PubMedCrossRef
70.
Ohkuri T, Kosaka A, Ikeura M, Salazar AM, Okada H. IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. J Immunother Cancer. 2021;9:e002426.PubMedPubMedCentralCrossRef
71.
Khan MSS, Majid AMSA, Iqbal MA, Majid ASA, Al-Mansoub M, Haque RSMA. Designing the angiogenic inhibitor for brain tumor via disruption of VEGF and IL17A expression. Eur J Pharm Sci. 2016;93:304–18.PubMedCrossRef
72.
Khan MSS, Asif M, Basheer MKA, Kang CW, Al-Suede FS, Ein OC, et al. Treatment of novel IL17A inhibitor in glioblastoma implementing 3rd generation co-culture cell line and patient-derived tumor model. Eur J Pharmacol. 2017;803:24–38.PubMedCrossRef
73.
74.
Ibrahim S, Girault A, Ohresser M, Lereclus E, Paintaud G, Lecomte T, et al. Monoclonal antibodies targeting the IL-17/IL-17RA axis: an opportunity to improve the efficiency of anti-VEGF therapy in fighting metastatic colorectal cancer? Clin Colorectal Cancer. 2018;17:e109–13.PubMedCrossRef
75.
Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23:38–54.PubMedCrossRef
76.
Lee YH, Chuah S, Nguyen PHD, Lim CJ, Lai HLH, Wasser M, et al. IFNγ-IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma. Cancer Lett. 2023;552:215977.PubMedCrossRef
77.
Doroudchi M, Pishe ZG, Malekzadeh M, Golmoghaddam H, Taghipour M, Ghaderi A. Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev. 2013;14:5225–30.PubMedCrossRef
78.
Sui L, Li Y, Xu Z, Shen X. Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation. J BUON. 2020;25:2608–15.PubMed
79.
Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, et al. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS ONE. 2015;10:e0126022.PubMedPubMedCentralCrossRef
80.
Shao J, Chen K, Li Q, Ma J, Ma Y, Lin Z, et al. High level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma. Cancer Manag Res. 2020;12:6261–8.PubMedPubMedCentralCrossRef
81.
Qian X, Chen H, Wu X, Hu L, Huang Q, Jin Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 2017;89:34–44.PubMedCrossRef
82.
Bronsart E, Derangere V, Boone M, Chauffert B, Ghiringhelli F. PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma. Ann Oncol. 2016;27:vi104.CrossRef
83.
Nijaguna MB, Patil V, Hegde AS, Chandramouli BA, Arivazhagan A, Santosh V, et al. An eighteen serum cytokine signature for discriminating glioma from normal healthy individuals. PLoS ONE. 2015;10:e0137524.PubMedPubMedCentralCrossRef
84.
Karaca F, Keskin S, Menteş S, Ökten A, Çavuş G, Arslan A, et al. Evaluation of IL-17A expressions in high-grade glial tumors receiving radiotherapy. Niger J Clin Pract. 2022;25:582.PubMedCrossRef
85.
86.
87.
Qian L, Guan J, Wu Y, Wang Q. Upregulated circular RNA circ_0074027 promotes glioblastoma cell growth and invasion by regulating miR-518a-5p/IL17RD signaling pathway. Biochem Biophys Res Commun. 2019;510:515–9.PubMedCrossRef
88.
Zeng C, Chen L, Chen B, Cai Y, Li P, Yan L, et al. Th17 cells were recruited and accumulated in the cerebrospinal fluid and correlated with the poor prognosis of anti-NMDAR encephalitis. Acta Biochim Biophys Sin. 2018;50:1266–73.PubMedCrossRef
89.
Levraut M, Bourg V, Capet N, Delourme A, Honnorat J, Thomas P, et al. Cerebrospinal fluid IL-17A could predict acute disease severity in Non-NMDA-receptor autoimmune encephalitis. Front Immunol. 2021;12:673021.PubMedPubMedCentralCrossRef
90.
91.
92.
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res CR. 2022;41:142.PubMedCrossRef
93.
Shireman JM, Gonugunta N, Zhao L, Pattnaik A, Distler E, Her S, et al. GM-CSF and IL-7 fusion cytokine engineered tumor vaccine generates long-term Th-17 memory cells and increases overall survival in aged syngeneic mouse models of glioblastoma. Aging Cell. 2023;22:e13864.PubMedPubMedCentralCrossRef
94.
Vedunova M, Turubanova V, Vershinina O, Savyuk M, Efimova I, Mishchenko T, et al. DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis. Cell Death Dis. 2022;13:1062.PubMedPubMedCentralCrossRef
95.
Yan Y, Fang M, Xuan W, Wu X, Meng X, Wang L, et al. The therapeutic potency of HSP65-GTL in GL261 glioma-bearing mice. J Immunother. 1997;2015(38):341–9.
96.
Ji M, Zhang Z, Lin S, Wang C, Jin J, Xue N, et al. The PI3K inhibitor XH30 enhances response to temozolomide in drug-resistant glioblastoma via the noncanonical hedgehog signaling pathway. Front Pharmacol. 2021;12:749242.PubMedPubMedCentralCrossRef
97.
98.
Khan MSS, Iqbal MA, Asif M, Azam T. Anti-GBM potential of rosmarinic acid and its synthetic derivatives via targeting IL17A mediated angiogenesis pathway. J Angiother. 2019;3:097–122.CrossRef
99.
Oliveira-Ferrer L, Wellbrock J, Bartsch U, Murga Penas EM, Hauschild J, Klokow M, et al. Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. Mol Cancer. 2013;12:144.PubMedPubMedCentralCrossRef
100.
Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir. 2018;58:405–21.CrossRef
101.
102.
Mahmoud AB, Ajina R, Aref S, Darwish M, Alsayb M, Taher M, et al. Advances in immunotherapy for glioblastoma multiforme. Front Immunol. 2022;13:944452.PubMedPubMedCentralCrossRef
103.
Mitsdoerffer M, Aly L, Barz M, Engleitner T, Sie C, Delbridge C, et al. The glioblastoma multiforme tumor site promotes the commitment of tumor-infiltrating lymphocytes to the TH17 lineage in humans. Proc Natl Acad Sci U S A. 2022;119:e2206208119.PubMedPubMedCentralCrossRef
104.
Nagaoka K, Shirai M, Taniguchi K, Hosoi A, Sun C, Kobayashi Y, et al. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy. J Immunother Cancer. 2020;8:e001358.PubMedPubMedCentralCrossRef
105.
Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, et al. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021;9:e001895.PubMedPubMedCentralCrossRef
106.
Wang S, Yu X, Li F, Fan H, Zhao E, Hu Z. Targeting IL-17alpha to promote anti-PD-1 therapy effect by screening the tumor immune microenvironment in a mouse oral carcinogenesis model. Cancer Biomark. 2021;31:339–50.PubMedCrossRef
107.
108.
Bălașa A, Șerban G, Chinezu R, Hurghiș C, Tămaș F, Manu D. The involvement of exosomes in glioblastoma development, diagnosis, prognosis, and treatment. Brain Sci. 2020;10:553.PubMedPubMedCentralCrossRef
109.
Mousavikia SN, Darvish L, Bahreyni Toossi MT, Azimian H. Exosomes: their role in the diagnosis, progression, metastasis, and treatment of glioblastoma. Life Sci. 2024;350:122743.PubMedCrossRef
110.
Liu F, Bu Z, Zhao F, Xiao D. Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells. Cancer Sci. 2018;109:65–73.PubMedCrossRef
111.
Sun J, Jia H, Bao X, Wu Y, Zhu T, Li R, et al. Tumor exosome promotes Th17 cell differentiation by transmitting the lncRNA CRNDE-h in colorectal cancer. Cell Death Dis. 2021;12:123.PubMedPubMedCentralCrossRef
112.
Bao H, Peng Z, Cheng X, Jian C, Li X, Shi Y, et al. GABA induced by sleep deprivation promotes the proliferation and migration of colon tumors through miR-223-3p endogenous pathway and exosome pathway. J Exp Clin Cancer Res CR. 2023;42:344.PubMedCrossRef
113.
Pakravan N, Abbasi A, Hassan ZM. Immunotherapy using oxygenated water and tumor-derived exosomes potentiates antitumor immune response and attenuates malignancy tendency in mice model of breast cancer. Oxid Med Cell Longev. 2021;2021:5529484.PubMedPubMedCentralCrossRef
Metadata
Title
The role of IL-17 in the pathogenesis and treatment of glioblastoma—an update on the state of the art and future perspectives
Authors
Dariusz Łaszczych
Aleksandra Czernicka
Karol Gostomczyk
Łukasz Szylberg
Jędrzej Borowczak
Publication date
01-08-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 8/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02434-1

Other articles of this Issue 8/2024

Genipin’s potential as an anti-cancer agent: from phytochemical origins to clinical prospects

Possible protective effect of rosuvastatin in chemotherapy-induced cardiotoxicity in HER2 positive breast cancer patients: a randomized controlled trial

PARK2 suppresses the proliferation of high-grade serous ovarian carcinoma via inducing the proteasomal degradation of ZNF703

The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy

Anticancer effects of Artemisia campestris extract on acute myeloid leukemia cells: an ex vivo study

A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar
Image Credits